News
Proud Collaboration Highlight from Path2 Patient Conference 2026
24/03/2026
Last week, on 19th March, our partner at Lund University delivered an inspiring talk at the Path2 Patient ATMP conference:
“Hyper‑Targeting pluripotent stem cell–derived Natural Killer cells for adoptive cell immunotherapy.”
Niels-Bjarne Wood’s presentation highlighted the rapidly advancing field of iPS‑derived immune cell therapies and showcased how next‑generation HyperTargIPS‑NK platforms can accelerate the future of allogeneic, off‑the‑shelf immunotherapies. Members from Magle Biopharma also attended.
Key themes included:
iPS‑derived NK cells (iPSC‑NK cells) engineered for enhanced cytotoxicity
Hyperactive NK cells driven by metabolic and TCA‑cycle modulation
GMP‑compatible iPSC manufacturing workflows enabling scalable, robust production
GMP‑scale NK cell production supporting future clinical translation
The promise of iPS cell–derived CAR‑NK therapy for broad oncology applications.
Advancements in allogeneic NK cell therapy designed for accessible, repeat‑dose treatment strategies
Events like this are a reminder of the incredible innovation happening in the Öresund region, where academia and industry collaborate closely to bring advanced therapies closer to patients.
You can read more about the event here
A huge thank‑you to our Lund University colleague for representing this exciting work and for driving forward the next generation of off‑the‑shelf NK cell therapy innovations!
Magle Biopharma had the pleasure of hosting the concluding scientific seminar of the HyperTargIPS-NK project.
11/03/2026
Last week, Magle Biopharma had the pleasure of hosting the concluding scientific seminar of the HyperTargIPS-NK project, bringing together academic and industry partners to reflect on the scientific progress achieved during this ambitious EU‑funded collaboration.
The seminar showcased how close, interdisciplinary collaboration can accelerate innovation in cell‑based immunotherapies, covering progress across the full value chain, from platform development and functional characterization to translational and manufacturing considerations.
Key themes included:
Advances in iPSC‑derived NK cell platform development
Strategies to enhance cell functionality and persistence
Progress in genetic engineering approaches tailored to NK biology
Data from preclinical models
Early alignment with GMP and regulatory expectations to support future clinical translation
Beyond the science, the seminar highlighted the strength of the consortium and the importance of aligning research excellence with translational readiness from an early stage.
A big thank you to all speakers and partners from Lund University, Hannover Medical School, Københavns Universitet – University of Copenhagen, and Magle Biopharma for their engagement, openness, and scientific rigor throughout the project.
This collaboration demonstrates how European partnerships can drive impactful innovation in advanced therapies.
Change in Project Coordinator from Amniotics to Magle Biopharma
17/04/2025
Change in Project Coordinator from Amniotics to Magle Biopharma
In October 2024, Magle Group completed a merger with Amniotics. Since then, Magle Group has continued Amniotics’ business operations in the company Magle Biopharma, which is part of the Magle Group suite of companies. Magle Biopharma has become the new project coordinator for the project, with Magle Chemoswed Holding registered as an associate company.
Read more about Magle Group
40 Million Swedish kronor to Natural Killer Cell research
24/08/2023
Tumor stem cells hide in the body and cause patients with aggressive cancers to often relapse. By programming genetically modified killer cells to “vacuum” up the remaining tumor stem cells, it is hoped to find more effective treatment options. The international research project led by Lund University has now been awarded 40 million by Horizon Europe, to tailor immunotherapy for AML, glioblastoma and pancreatic cancer.
